RA0817

antibody from Oursmab

Targeting: VTCN1 B7-H4, B7H4, B7S1, B7x, FLJ22418

Western blot (Data presented on provider website)

ELISA (Data presented on provider website)

Immunocytochemistry (Recommended by provider)

Flow cytometry (Recommended by provider)

Functional assay (Recommended by provider)

Antibody Data

Product number

RA0817

Provider

Oursmab

Product name

Alsevalimab (Biosimilar Reference Antibody) (VTCN1)

Antibody type

Monoclonal

Description

Alsevalimab (formerly FPA-150) is a humanized, glycoengineered monoclonal antibody of the IgG1 isotype. It functions as an immune checkpoint inhibitor by targeting and blocking B7-H4 (VTCN1). The antibody is afucosylated in its Fc region, a modification designed to enhance its binding affinity to CD16 receptors on Natural Killer (NK) cells. This modification significantly boosts its ability to induce Antibody-Dependent Cellular Cytotoxicity (ADCC) against tumor cells expressing B7-H4. By combining checkpoint blockade (abrogating the negative T-cell regulation) with direct tumor cell killing (via ADCC), Alsevalimab aims to enhance the overall anti-tumor immune response. It has been investigated in clinical trials for various solid tumors, particularly gynecological and gastrointestinal malignancies.

Reactivity

Human

Isotype

IgG

Vial size

100 ¦Ìg,1 mg,5 mg,10 mg,25 mg,50 mg,100 mg

Concentration

Bottled at the concentration indicated on the vial.

Storage

Store at -20¡ãC or -80¡ãC. Avoid repeated freeze.